What's Happening?
Dr. Tobias Janowitz has been appointed as the new director of the Institute of Cancer Research at the Feinstein Institutes for Medical Research. In addition to this role, he will serve as the Robert and Janet Perro Professor in Cancer Research and director of Translational
Cancer Research at Northwell Health’s Cancer Institute. Dr. Janowitz will also continue to lead his established research program at Cold Spring Harbor Laboratory (CSHL) Cancer Center, fostering a closer strategic affiliation between CSHL and Northwell. With over 20 years of experience, Dr. Janowitz's research focuses on the mechanisms driving cancer progression, particularly the metabolic, neuroendocrine, and immune circuits that influence disease progression and therapeutic response. His team has demonstrated how systemic stress from tumors alters energy metabolism, elevates stress hormones, and weakens the immune system, contributing to cancer cachexia. As a gastrointestinal oncologist, his goal is to redefine cancer treatment by focusing on the entire patient, not just the tumor.
Why It's Important?
Dr. Janowitz's appointment is a significant development for cancer research and treatment in the United States, particularly within the Northwell Health system. His leadership is expected to enhance the Feinstein Institutes' efforts to produce knowledge that cures disease and improve cancer treatment through clinical trials and basic and translational science. His expertise in understanding the systemic effects of cancer, such as cachexia, addresses a critical, often overlooked aspect of patient care that significantly impacts quality of life and treatment outcomes. By integrating his research with clinical practice, Dr. Janowitz aims to develop more holistic treatment approaches. The strengthened collaboration between the Feinstein Institutes and Cold Spring Harbor Laboratory under his guidance is poised to attract additional scientific expertise and accelerate the translation of research findings into new diagnostic and treatment options for millions of cancer patients. This move underscores a commitment to advancing personalized and comprehensive cancer care.
What's Next?
Dr. Janowitz will continue to lead his research program at Cold Spring Harbor Laboratory while taking on his new leadership roles at the Feinstein Institutes and Northwell Health’s Cancer Institute. His immediate focus will be on fostering closer collaboration between these institutions to advance cancer diagnostic and treatment options. This will likely involve attracting more scientific talent and expanding research initiatives into the metabolic, neuroendocrine, and immune aspects of cancer. The Northwell-START New York-Long Island facility, an early-phase cancer clinical trial center, will be a key platform for translating Dr. Janowitz's research into clinical applications. The goal is to develop innovative therapies that address the entire patient, moving beyond tumor-centric treatments. His dual role as a clinician and laboratory scientist will ensure that research remains closely aligned with patient needs and clinical challenges.
Beyond the Headlines
Dr. Janowitz's approach to cancer research, which emphasizes the systemic impact of the disease on the patient's body, represents a crucial evolution in oncology. Traditionally, cancer research has often focused primarily on the tumor itself. However, understanding how cancer alters the body's metabolism, hormonal balance, and immune system, as in the case of cancer cachexia, can lead to more effective and humane treatments. This holistic perspective has the potential to not only improve survival rates but also significantly enhance the quality of life for cancer patients. The integration of a clinician-scientist like Dr. Janowitz into a leadership role at a major research institute highlights the growing recognition of the importance of bridging the gap between basic science and clinical care. This could inspire a new generation of researchers to adopt a more comprehensive view of disease, leading to more integrated and patient-centered medical innovations.
